Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) saw a large drop in short interest in the month of October. As of October 30th, there was short interest totaling 14,956 shares, a drop of 52.2% from the October 15th total of 31,307 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 27,864 shares, the short-interest ratio is presently 0.5 days.
Shuttle Pharmaceuticals Stock Performance
Shares of Shuttle Pharmaceuticals stock traded down $0.01 on Monday, hitting $4.53. The company had a trading volume of 21,429 shares, compared to its average volume of 725,884. Shuttle Pharmaceuticals has a 1 year low of $2.58 and a 1 year high of $44.40. The stock has a 50 day moving average of $4.49 and a 200-day moving average of $6.41. The stock has a market capitalization of $21.56 million, a price-to-earnings ratio of -0.24 and a beta of -0.04.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, November 10th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Shuttle Pharmaceuticals presently has a consensus rating of “Sell”.
Read Our Latest Report on SHPH
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue. Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.
See Also
- Five stocks we like better than Shuttle Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
